Our Publications

Name: Be Like Water Media Inc.
Price range: $

Cambridge Cardiac Care Affiliated Publications

Cambridge Cardiac Care is among the nation’s leaders in clinical cardiometabolic research. Investigating the nature of this family of diseases and developing new therapies & novel medical devices, we are committed to doing our part to propel the science and practice of cardiology into the future.

Etripamil Nasal Spray Reduces Heart Rate in Patients With Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

Paroxysmal supraventricular tachycardia (PSVT) is characterized by intermittent episodes of tachycardia with sudden onset and termination. The NODE-301 study evaluated self-administration of etripamil nasal spray 70 mg in a medically unsupervised (generally at home) setting for acute PSVT termination. Self-administration of intranasal etripamil rapidly and significantly decreased HR in PSVT…

Right heart pulmonary embolism in transit: a review of therapeutic considerations.

The presence of a right heart clot in the setting of pulmonary emboli carries a very high mortality rate and warrants urgent therapy, which may include anticoagulation, thrombolysis or surgical embolectomy. Because limited information is available, therapy must be individualized based on patient characteristics, clot location and local expertise. The pertinent literature is reviewed and…

The Differential Effects of Valsartan/Sacubirtril on Cardiac Function in Ischemic versus Dilated Cardiomyopathy: A 1 Year Real World Study

In HFrEF CHF patients on optimal medical therapy, the switch of ACE-i to ARNI resulted in significant improvements in LV EF at 1 year. Greater improvements were noted in patients with dilated than ischemic CM. This study may provide insight into cardiac function mechanisms that lead to the marked clinical improvements noted in the PARADIGM-HF study.

Correlates Of Aortic Valve Calcification In Aortic Stenosis: Insights From The Astronomer Study

In patients with AS, age and male sex are the main correlates of AVC. After adjusting for age, AVC is not associated with AV morphology but appears to be related to male sex, BP and LDL-C. Thus BP and LDL-C are promising modifiable targets to prevent AVC which in turn should reduce AS progression.

INTERACTION BETWEEN ROSUVASTATIN AND HIGH SENSITIVITY C-REACTIVE PROTEIN ON PROGRESSION OF AORTIC STENOSIS

Aortic stenosis (AS) has been shown to be an active process in which inflammation appears to play an integral part. High sensitivity C-reactive protein (CRP) is a sensitive marker of inflammation. The purposes of this study were to assess the impact of CRP on AS progression, and to assess the effect of rosuvastatin on CRP levels and AS progression. We found no interaction between treatment…

Atherosclerosis Imaging and the Canadian Atherosclerosis Imaging Network

Atherosclerosis exacts a large toll on society in the form of cardiovascular morbidity, mortality, and resource use and is exacerbated by the epidemics of obesity and diabetes. Consequently, there is a critical need for more-effective methods of diagnosis, treatment, and prevention of the complications of atherosclerosis. Cambridge Cardiac Care Centre is part of the Canadian Atherosclerosis…

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral…

Comparison of Rosuvastatin Versus Atorvastatin in South-Asian Patients at Risk of Coronary Heart Disease (from the IRIS Trial)

In a large randomized trial of statin therapy in patients of South-Asian origin with hypercholesterolemia, 740 patients in the United States and Canada received 6 weeks of treatment with rosuvastatin 10 or 20 mg or atorvastatin 10 or 20 mg. We found that statin therapy was well tolerated and effective in decreasing LDL cholesterol in patients of South-Asian origin, with the 10- and 20-mg doses…

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death.

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated.

Page 5 of 7